Payment overview · 2025
General Payments
$363.62
19 reported records · 11 companies
Healthcare provider profile · identity verified
Vincent Muller, PHYSICIAN ASSISTANT
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SOCORRO, NM · NPI 1053412692
Verified facts
What the public records show
CMS Open Payments records show Vincent Muller, PHYSICIAN ASSISTANT received $363.62 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.21 | 17.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $58.95 | 16.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.68 | 12.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.92 | 10.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.50 | 9.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.54 | 6.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.42 | 5.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.29 | 5.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.25 | 5.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.91 | 5.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.95 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.62 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.21 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $58.95 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.92 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.92 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 277 | 226 |
| Lisinopril | Lisinopril | 242 | 94 |
| Gabapentin | Gabapentin | 215 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 141 |
| Omeprazole | Omeprazole | 171 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 164 | 79 |
| Ibuprofen | Ibuprofen | 159 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 158 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 145 | 42 |
| Metformin Hcl | Metformin Hcl | 113 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 33 |
| Trazodone Hcl | Trazodone Hcl | 102 | 34 |
| Losartan Potassium | Losartan Potassium | 97 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 47 |
| Azithromycin | Azithromycin | 88 | 78 |
| Glimepiride | Glimepiride | 85 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 30 |
| Alprazolam | Alprazolam | 70 | 22 |
| Cephalexin | Cephalexin | 69 | 65 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 65 |
| Lorazepam | Lorazepam | 68 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 16 |
| Famotidine | Famotidine | 57 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 24 |
| Potassium Chloride | Potassium Chloride | 52 | 23 |
| Baclofen | Baclofen | 50 | 30 |
| Finasteride | Finasteride | 49 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 47 |
| Fluconazole | Fluconazole | 45 | 33 |
| Naproxen | Naproxen | 43 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 18 |
| Alendronate Sodium | Alendronate Sodium | 40 | 15 |
| Doxepin Hcl | Doxepin Hcl | 40 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 18 |
| Ondansetron Odt | Ondansetron | 39 | 23 |
| Sertraline Hcl | Sertraline Hcl | 39 | 15 |
| Furosemide | Furosemide | 38 | 22 |
| Simvastatin | Simvastatin | 38 | 17 |
| Pregabalin | Pregabalin | 36 | 14 |
| Amoxicillin | Amoxicillin | 35 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 16 |
| Carvedilol | Carvedilol | 32 | 17 |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Eliquis | Apixaban | 31 | 12 |
| Lactulose | Lactulose | 31 | 21 |
| Allopurinol | Allopurinol | 30 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 20 |
| Ibu | Ibuprofen | 30 | 17 |
| Clonazepam | Clonazepam | 28 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 26 | suppressed |
| Atenolol | Atenolol | 25 | 12 |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | 13 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 12 |
| Lovastatin | Lovastatin | 24 | 11 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | 11 |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 15 |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | 11 |
| Temazepam | Temazepam | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | 11 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.62 · 19 records | ABBVIE INC. | BREZTRI, CAPLYTA, Kerendia, Ozempic, PAXLOVID, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN, YUPELRI, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error